EU Authorised Representative for Medical Devices and IVDs Across Europe
For manufacturers based outside the European Union, bringing medical devices or in vitro diagnostic devices into the European market involves more than product quality, technical documentation and regulatory preparation. Before any device is introduced to the European market, the manufacturer must appoint an EU Authorized Representative who is physically located in the European Union and legally recognised as the manufacturer’s official representative. This function is critical under the Medical Device Regulation and the In Vitro Diagnostic Medical Device Regulation as regulators require a responsible local entity to manage communication, supply documentation and assist with compliance obligations when needed. An eu-authorized-representative is far more than just a name printed on a label. They serve as the legal presence of a non-EU manufacturer and play a vital role in ensuring market access, regulatory trust and ongoing post-market accountability.
Why an EU Authorized Representative Is Required
European medical device rules are designed to protect patients, healthcare professionals and users by ensuring that every product placed on the market has a clear chain of responsibility. When a manufacturer is based outside the European Union, regulators cannot always deal with that manufacturer directly in the same practical way they would with a local company. This is exactly where the EU Authorized Representative becomes essential. The representative provides a formal local presence and serves as the official point of communication for Competent Authorities, Notified Bodies and other regulatory stakeholders.
Without appointing an authorised representative, a non-EU manufacturer cannot legally place medical devices or IVDs on the European market. This applies to a wide range of products, from simple low-risk devices to complex diagnostic technologies. This obligation applies before market entry, meaning the representative must be selected early in the compliance journey rather than as a last administrative step. For companies preparing for European distribution, selecting the right EU Authorized Representative for Medical Devices and IVDs can significantly influence registration readiness, document management and long-term regulatory stability.
The Written Mandate Between Manufacturer and Representative
The connection between the manufacturer and the EU Authorized Representative must be formalised through a written mandate. This mandate defines the tasks the representative is authorised to perform and confirms the obligations both parties must follow. It is a key compliance document because it sets out the scope of representation, responsibilities, communication duties and actions required if compliance concerns arise.
A vague or poorly prepared mandate can create uncertainty at the worst possible time, especially during an authority request, inspection, complaint review or corrective action. A strong mandate should clearly describe how documents will be made available, how regulatory communication will be handled, how incident information will be shared and what happens if the manufacturer does not meet its duties. For this reason, the mandate should be prepared carefully and reviewed before device registration or market placement begins.
Label and Packaging Requirements
The name and address of the EU Authorized Representative must appear on the device label, packaging or related product information as required by the applicable regulation. This enables authorities, distributors, healthcare professionals and users to identify the local representative connected to the device. It also reinforces the representative’s role as the official European presence for a manufacturer located outside the European Union.
Accurate labelling is essential because incorrect or missing representative details can lead to compliance issues and possible delays in market access. Manufacturers should ensure that their artwork, instructions, declarations and registration information are aligned before products are released. If the representative is changed, labelling and registration details may also require timely and controlled updates.
Documentation Review and Availability
A key responsibility of an EU Authorized Representative for Medical Devices and IVDs is to ensure that essential compliance documents are available and correctly prepared. This includes checking that the EU Declaration of Conformity exists, that technical documentation has been compiled and that the manufacturer has followed an appropriate conformity assessment route for the device type and risk class.
The representative may also need to hold or have access to copies of technical documentation, declarations and Notified Body certificates. These documents must be available for inspection by Competent Authorities for the required retention period after the last device has been placed on the market. This makes document control a central part of the relationship between manufacturer and representative. Manufacturers should maintain updated records eu-authorized-representative and ensure that the representative can respond quickly if regulators request information.
Communication With Competent Authorities and Notified Bodies
The EU Authorized Representative acts as the official communication channel between the non-EU manufacturer and European regulatory authorities. If a Competent Authority requests information, samples, technical documentation or clarification, the representative is expected to support the response process. The representative may also communicate with Notified Bodies when required, especially where certificates, conformity assessment or corrective actions are involved.
This communication function goes beyond simply passing messages. A reliable representative should understand regulatory expectations, keep accurate records and ensure that requests are handled within appropriate timelines. Late or incomplete replies can lead to serious consequences, including market limitations or additional regulatory scrutiny. For this reason, manufacturers should work with a representative who has strong regulatory knowledge and clear internal processes.
Post-Market Surveillance and Incident Support
Compliance for medical devices does not stop once the product reaches the market. Once a device is in use, manufacturers must continue monitoring performance, complaints, incidents and safety signals. The EU Authorized Representative supports this post-market obligation by promptly forwarding complaints and incident reports to the manufacturer.
This is particularly critical when information originates from clinicians, patients, users, distributors or authorities. Timely reporting allows the manufacturer to determine whether investigation, reporting, field safety actions or corrective measures are required. A strong representative understands that post-market surveillance is not just paperwork. It plays a key role in patient safety, product enhancement and continued regulatory confidence.
Registration Responsibilities and EUDAMED
Within European regulatory frameworks, manufacturer and representative details must be registered as necessary. The EU Authorized Representative may assist with registering both manufacturer and representative data in EUDAMED. Accurate registration enables authorities to identify responsible entities, review device data and maintain market supervision.
Manufacturers should gather complete company information, device details, certificates and declarations before starting registration. Any inconsistency between labels, declarations, technical files and registration records can create delays or compliance questions. The representative’s involvement helps ensure that required information is properly aligned and available when needed.
When the Representative Must Take Action
An EU Authorized Representative also carries responsibilities if the manufacturer does not fulfil regulatory requirements. If significant non-compliance arises and is not corrected by the manufacturer, the representative may need to terminate the mandate and notify relevant authorities and the Notified Body where relevant. This responsibility shows why the role is more than administrative.
The representative has legal accountability and cannot ignore major compliance failures. Manufacturers should therefore view the representative as a regulatory partner rather than a passive provider. Open communication, timely document updates and clear responsibility sharing help prevent misunderstandings and reduce risk during the product life cycle.
Choosing the Right EU Authorized Representative
Selecting an EU Authorized Representative should be done with care. Manufacturers should evaluate regulatory expertise, experience in medical devices and IVDs, document management capabilities, clear response processes and strong knowledge of European regulations. The representative should effectively handle authority communication, maintain records and guide the manufacturer on practical compliance matters.
Cost alone should not determine the choice. An ineffective representative may lead to delays, communication gaps and increased risk, whereas a strong representative can support confidence during market entry and beyond. The correct selection provides non-EU manufacturers with a reliable European presence and enables smoother regulatory management.
Conclusion
An EU Authorized Representative is a mandatory requirement for non-EU manufacturers aiming to introduce medical devices or IVDs into the European market. The role covers legal representation, document availability, regulatory communication, complaint management, registration assistance and intervention in cases of serious non-compliance. Under the Medical Device Regulation and In Vitro Diagnostic Medical Device Regulation, appointing an authorised representative is not optional and should be completed before market placement begins. By choosing a competent EU Authorized Representative for Medical Devices and IVDs, manufacturers can strengthen compliance, support patient safety and build a reliable foundation for long-term access to the European market.